GlucoTrack (GCTK) AI Stock Analysis

• Market Cap: $1.74M
• Dividend Yield: N/A
• Average Volume (3M): 2.54M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.99
• Revenue Growth: N/A
• EPS Growth: 60.83%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -4.64
• Shares Outstanding: 910,688
• 10 Day Avg. Volume: 100,775
• 30 Day Avg. Volume: 2,541,249
• PEG Ratio: 0.03
• Price to Book (P/B): -12.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.22
• Enterprise Value/Market Cap: -3.92
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 158.71
• Enterprise Value/Ebitda: 0.27
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $2.00 ▲(3.63% Upside)

The score is primarily weighed down by very weak financial performance (minimal revenue, widening losses, rising cash burn, and negative equity). Technicals also detract due to a strong downtrend despite oversold readings. Corporate events provide some offset via improved IP positioning and added capital, but valuation remains constrained by ongoing losses and no dividend.

Positive Factors

Strengthened IP portfolio

The issuance of three patents for the continuous blood glucose monitoring platform creates durable barriers to entry around sensor chemistry, intravascular lead design and low-power electronics. This strengthens bargaining power with partners and defends commercialization efforts over the coming quarters.

Differentiated implantable CBGM strategy

A multi‑year, fully implantable CBGM targets an unmet need vs short-lived subcutaneous sensors, offering a structurally differentiated product proposition. If clinical progress continues, this product strategy supports durable market opportunity and long-term adoption potential in diabetes care.

Near-term liquidity improvement

The $4.0M private placement, with lock-ups, exercise caps and registration commitments, provides runway for ongoing clinical and development activities. The financing also constrains dilution pathways temporarily, reducing immediate solvency pressure and enabling execution over the next several months.

Negative Factors

No meaningful revenue base

Sustained lack of revenue indicates the business has not achieved commercial traction. Without recurring sales, the company depends on funding to advance trials and commercialization, increasing execution and commercialization risk across a multi‑quarter horizon until meaningful revenue is established.

Severe and growing cash burn

Material negative operating and free cash flow that has worsened to ~-$12.5M annually signals heavy funding needs. Persistent cash burn without revenues implies repeated capital raises, dilutive financing, and heightened execution risk for sustaining clinical programs over the next several quarters.

Negative equity and solvency risk

A sharp shift to materially negative equity reflects accumulated losses and weak capitalization. Even with low absolute debt, negative equity constrains financing options, raises the cost of capital and increases the risk of funding stress or restructuring during the next few quarters if operational progress stalls.

GlucoTrack Business Overview & Revenue Model

Company Description

GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.

How the Company Makes Money

GlucoTrack generates revenue primarily through the sale of its non-invasive glucose monitoring devices. The company's key revenue streams include direct sales of its products to consumers and healthcare providers, as well as potential licensing agreements and partnerships with other medical device companies or healthcare institutions. Additionally, GlucoTrack may explore subscription-based models for device usage and data management services, providing a recurring revenue stream. Strategic partnerships with diabetes care organizations and healthcare providers can also contribute to its earnings by expanding the market reach and adoption of its technology.

GlucoTrack Financial Statement Overview

Summary

Financial quality is very weak: revenue is effectively zero in recent years, losses have widened materially, and cash burn has worsened. Despite low absolute debt, the shift to meaningfully negative equity in 2024 increases solvency and funding risk.

Income Statement

Operating performance is very weak and deteriorating. Revenue is effectively zero from 2020–2024, while losses have widened materially (net loss of about $2.7M in 2020 rising to about $22.6M in 2024). Profitability is consistently negative (negative gross profit and deeply negative operating results), indicating the cost structure is not supported by current commercial scale. A modest positive in the dataset is that reported revenue growth was strong in 2019, but it did not translate into sustained revenues in subsequent years.

Balance Sheet

Leverage looks low in absolute dollars (total debt is only ~$0.2–0.4M across periods), which reduces near-term balance sheet pressure. However, the capital structure has weakened sharply: stockholders’ equity swung from positive (~$3.2M in 2023) to meaningfully negative (~-$13.0M in 2024), a major red flag that reflects accumulated losses and raises financing risk. Total assets increased to ~$5.9M in 2024, but the negative equity position and continued losses outweigh the benefit of a relatively small debt load.

Cash Flow

Cash generation is persistently negative and worsening. Operating cash flow is consistently outflowing (from about -$3.5M in 2020 to about -$12.5M in 2024), and free cash flow remains negative each year (about -$12.6M in 2024). While free cash flow to net income is near 1.0 (cash losses roughly match accounting losses), the underlying issue is the scale of ongoing cash burn with no evident revenue base in recent years, implying continued reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-43.00K	-36.00K	-13.00K	-23.00K	0.00	-47.00K
EBITDA	-24.88M	-21.98M	-7.08M	-4.41M	-3.94M	-2.65M
Net Income	-26.77M	-22.60M	-7.10M	-4.43M	-4.07M	-2.70M
Balance Sheet
Total Assets	10.21M	5.93M	4.91M	2.44M	6.26M	10.61M
Cash, Cash Equivalents and Short-Term Investments	9.55M	5.62M	4.49M	2.31M	6.06M	9.82M
Total Debt	267.00K	267.00K	196.00K	195.00K	250.00K	363.00K
Total Liabilities	3.33M	18.93M	1.71M	1.21M	1.11M	1.62M
Stockholders Equity	6.88M	-13.00M	3.20M	1.23M	5.16M	8.98M
Cash Flow
Free Cash Flow	-14.37M	-12.59M	-6.56M	-3.73M	-3.77M	-3.55M
Operating Cash Flow	-14.32M	-12.49M	-6.56M	-3.73M	-3.77M	-3.50M
Investing Cash Flow	-42.00K	-104.00K	0.00	1.00K	-1.00K	-53.00K
Financing Cash Flow	23.72M	13.74M	8.73M	0.00	0.00	13.01M

GlucoTrack Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.93
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GCTK, the sentiment is Negative. The current price of 1.9300000000000002 is below the 20-day moving average (MA) of 3.49, below the 50-day MA of 4.48, and below the 200-day MA of 6.34, indicating a bearish trend. The MACD of -0.58 indicates Positive momentum. The RSI at 20.62 is Positive, neither overbought nor oversold. The STOCH value of 5.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GCTK.

GlucoTrack Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EKSO	54 Neutral	$29.52M	-1.68	-85.01%	―	-16.59%	43.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WOK	44 Neutral	$1.90M	-0.01	―	―	―	―
GCTK	42 Neutral	$1.74M	>-0.01	―	―	―	60.83%
FEMY	41 Neutral	$31.85M	-0.72	-376.23%	―	63.53%	12.49%

GlucoTrack Corporate Events

GlucoTrack Strengthens IP for Implantable Glucose Monitoring Platform

On January 29, 2026, Glucotrack, Inc. announced that the U.S. Patent and Trademark Office had issued three patents in late 2025 covering key technologies underpinning its fully implantable continuous blood glucose monitoring platform, including proprietary sensor chemistry, intravascular lead design, and low-power electronics, which together aim to bridge the gap between short-lived subcutaneous sensors and larger pacemaker-class devices. The new patents bolster Glucotrack’s intellectual property protection and competitive position as it advances its multi-year CBGM system—designed to directly measure glucose from blood for up to three years of continuous, lag-free monitoring without a wearable component—through further clinical testing and toward eventual commercialization, reinforcing its strategic push to offer a more convenient, less burdensome diabetes management solution.

The most recent analyst rating on (GCTK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on GlucoTrack stock, see the GCTK Stock Forecast page.

GlucoTrack strengthens capital position with new private placement

On December 29, 2025, Glucotrack, Inc. entered into a securities purchase agreement with a single institutional investor for a private placement of pre-funded warrants and common warrants (or common stock equivalents) priced at-the-market under Nasdaq rules, raising approximately $4.0 million in gross proceeds at an effective combined price of $3.87 per share and warrant, with closing occurring on December 31, 2025. The financing, conducted through Curvature Securities LLC as sole placement agent, includes lock-up commitments from officers and directors, ownership caps on warrant exercises, restrictions on additional equity issuance and variable-rate financings for defined periods, and a registration rights framework that will require Glucotrack to register the resale of the underlying securities, collectively reinforcing its near-term capital position for working capital and general corporate purposes while constraining dilution pathways and shaping its funding strategy over the next year.

The most recent analyst rating on (GCTK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on GlucoTrack stock, see the GCTK Stock Forecast page.

GlucoTrack Issues Investor Presentation Under Regulation FD

On December 29, 2025, GlucoTrack, Inc., a Delaware corporation, issued an investor presentation to its shareholders and the broader market. The materials, which were provided as an investor update rather than a formal securities filing, were explicitly designated as not being subject to the liability provisions applicable to documents deemed filed under the Securities Exchange Act of 1934, underscoring that the presentation serves primarily as informational disclosure for investors rather than a binding regulatory submission.

GlucoTrack Announces Special Shareholders Meeting for Equity Deal

On November 3, 2025, Glucotrack, Inc. announced the reconvening of a Special Meeting of Shareholders on November 7, 2025, to vote on an Equity Purchase Agreement with Sixth Borough Capital Fund. This agreement, compliant with NASDAQ Listing Rule 5635(d), allows the issuance of more than 20% of the company’s common stock, potentially raising $20 million. The company urges all eligible shareholders to vote promptly to ensure their shares are represented, emphasizing the importance of participation in shaping the company’s financial future.